Fig. 6From: Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinomaTMB has limiting effects on predicting the efficacy of ICIs and prognostic assessment in ACC. TMB, tumor mutational burden; ACC, adrenocortical carcinoma; ICIs, immune checkpoints inhibitors; NSCLC, non-small-cell lung cancerBack to article page